Phaseline

Targets › FGF2

FGF2 (Fibroblast growth factor 2): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.

Acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signaling. (UniProt, P09038)

Open in Phaseline: the race on FGF2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
D. Bradley Welling, MD, PhDFibroblast Growth Factor 2 (FGF2)
Fibroblast growth factor 2 (FGF2) promotes cell proliferation and tissue repair
FGF2Phase 1Chronic Tympanic Membrane PerforationDec 2026

Conditions

Chronic Tympanic Membrane Perforation (1)

Modalities

small molecule (1)

Companies

D. Bradley Welling, MD, PhD (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.